603229 Stock Overview
Engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Zhejiang Ausun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.99 |
| 52 Week High | CN¥9.94 |
| 52 Week Low | CN¥5.76 |
| Beta | -0.019 |
| 1 Month Change | 19.50% |
| 3 Month Change | 19.78% |
| 1 Year Change | 6.28% |
| 3 Year Change | -23.60% |
| 5 Year Change | 125.20% |
| Change since IPO | 309.36% |
Recent News & Updates
Is Zhejiang Ausun Pharmaceutical (SHSE:603229) Using Too Much Debt?
Dec 20
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08Recent updates
Is Zhejiang Ausun Pharmaceutical (SHSE:603229) Using Too Much Debt?
Dec 20There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet
Jul 31Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified
Mar 06Shareholder Returns
| 603229 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 7.1% | -0.08% | 1.0% |
| 1Y | 6.3% | -6.0% | 8.2% |
Return vs Industry: 603229 exceeded the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 603229 underperformed the CN Market which returned 8.2% over the past year.
Price Volatility
| 603229 volatility | |
|---|---|
| 603229 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 603229 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603229's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,174 | Zhiguo Zheng | www.ausunpharm.com |
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications.
Zhejiang Ausun Pharmaceutical Co., Ltd. Fundamentals Summary
| 603229 fundamental statistics | |
|---|---|
| Market cap | CN¥8.25b |
| Earnings (TTM) | CN¥257.55m |
| Revenue (TTM) | CN¥835.23m |
32.2x
P/E Ratio9.9x
P/S RatioIs 603229 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603229 income statement (TTM) | |
|---|---|
| Revenue | CN¥835.23m |
| Cost of Revenue | CN¥377.58m |
| Gross Profit | CN¥457.65m |
| Other Expenses | CN¥200.10m |
| Earnings | CN¥257.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 30, 2025
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 54.79% |
| Net Profit Margin | 30.84% |
| Debt/Equity Ratio | 13.1% |
How did 603229 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 16:30 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Ausun Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Feifei Xu | China Merchants Securities Co. Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |